KINETA INC

YTD

ALL

Why Robinhood?

You can watch KINETA INC and buy or sell other stocks, ETFs, and their options commission-free!

About KANT

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb.

CEO

Shawn P. Iadonato, PhD

CEOShawn P. Iadonato, PhD

Employees

Employees5

Headquarters

Mercer Island, Washington

HeadquartersMercer Island, Washington

Founded

2008

Founded2008

Employees

Employees5

KANT Key Statistics

Market cap

3.95M

Market cap3.95M

Price-Earnings ratio

-0.21

Price-Earnings ratio-0.21

Dividend yield

—

Dividend yield—

Average volume

6.49K

Average volume6.49K

High today

$0.292

High today$0.292

Low today

$0.292

Low today$0.292

Open price

$0.292

Open price$0.292

Volume

3.00

Volume3.00

52 Week high

$1.15

52 Week high$1.15

52 Week low

$0.1921

52 Week low$0.1921

People also own

Based on the portfolios of people who own KANT. This list is generated using Robinhood data, and it’s not a recommendation.

KINETA INC

Why Robinhood?

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. Show more

KANT Key Statistics

People also own

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb.